When tested in an ex vivo study with human CML and ALL cells, and within in vivo with-mice xenograft models, the PROTAC demonstrates the enormous potential for the treatment of LK-Ph+ and even in some forms that have resistance to imatinib, being non-toxic and non-immunogenic and outperforming the results obtained by either nutlin, imatinib, or BCR/Abl-R6 [74,75]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.